Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts
Launched by VESALIO · Mar 24, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥22
- • 2. Symptomatic cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage (aSAH) in the internal carotid artery (ICA), middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), or basilar artery (BA)
- • 3. Vessel dilation procedure was performed with the NeVa VS
- • 4. Subject or legal representative is able and willing to give informed consent within 3 days (72 hours) post-index procedure
- Exclusion Criteria:
- • None
About Vesalio
Vesalio is a pioneering medical device company dedicated to advancing vascular health through innovative technologies. Specializing in the development of cutting-edge neurovascular solutions, Vesalio focuses on enhancing the treatment of complex conditions such as stroke and aneurysms. With a commitment to clinical excellence and patient safety, the company collaborates with leading healthcare professionals to conduct rigorous clinical trials that validate the efficacy and safety of its products. By integrating advanced engineering and clinical insights, Vesalio aims to improve patient outcomes and set new standards in the field of vascular intervention.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
